FDA Grants Fast Track to Faeth's Piktor Combo in Endometrial Cancer
FTH has more than doubled off its 52-week low of $7.21 on elevated volume (2.0× avg).
Summary
The FDA granted Fast Track designation to Faeth's Piktor plus paclitaxel for biomarker-selected advanced endometrial cancer, a regulatory milestone that can speed development and review. The company also disclosed topline Phase 2 data in this indication is expected by year-end 2026, with interim Phase 1b/2 breast cancer data in 2027. This follows Q2 results showing a $16M net loss and $186.4M cash, and a recent insider sale of ~$3.6M by a 10% holder. Fast Track status validates the program's potential in a high-need cancer setting and sets a near-term data catalyst.
At the time of this announcement, FTH was trading at $32.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $835.7M. The 52-week trading range was $7.21 to $37.90. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.